CL2016003295A1 - Dosificación intermitente de un inhibidor de mdm2. - Google Patents
Dosificación intermitente de un inhibidor de mdm2.Info
- Publication number
- CL2016003295A1 CL2016003295A1 CL2016003295A CL2016003295A CL2016003295A1 CL 2016003295 A1 CL2016003295 A1 CL 2016003295A1 CL 2016003295 A CL2016003295 A CL 2016003295A CL 2016003295 A CL2016003295 A CL 2016003295A CL 2016003295 A1 CL2016003295 A1 CL 2016003295A1
- Authority
- CL
- Chile
- Prior art keywords
- mdm2 inhibitor
- mdm2i
- mdm2
- treatment
- intermittent dosing
- Prior art date
Links
- 239000012819 MDM2-Inhibitor Substances 0.000 title abstract 4
- 229940083338 MDM2 inhibitor Drugs 0.000 title abstract 3
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462017406P | 2014-06-26 | 2014-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016003295A1 true CL2016003295A1 (es) | 2017-07-28 |
Family
ID=53510950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016003295A CL2016003295A1 (es) | 2014-06-26 | 2016-12-22 | Dosificación intermitente de un inhibidor de mdm2. |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US20170196866A1 (enExample) |
| EP (1) | EP3160463B1 (enExample) |
| JP (1) | JP6728072B2 (enExample) |
| KR (3) | KR102462177B1 (enExample) |
| CN (2) | CN106456635A (enExample) |
| AU (1) | AU2015278765B2 (enExample) |
| BR (1) | BR112016029750A2 (enExample) |
| CA (1) | CA2953079C (enExample) |
| CL (1) | CL2016003295A1 (enExample) |
| ES (1) | ES2856210T3 (enExample) |
| IL (1) | IL249138B (enExample) |
| MX (1) | MX2016017075A (enExample) |
| PH (1) | PH12016502556A1 (enExample) |
| RU (1) | RU2695228C2 (enExample) |
| SG (1) | SG11201609853VA (enExample) |
| TN (1) | TN2016000522A1 (enExample) |
| TW (1) | TW201613576A (enExample) |
| WO (1) | WO2015198266A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2682174C (en) | 2007-03-28 | 2021-04-06 | President And Fellows Of Harvard College | Stitched polypeptides |
| KR20130099938A (ko) | 2010-08-13 | 2013-09-06 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| CN104039342A (zh) | 2011-10-18 | 2014-09-10 | 爱勒让治疗公司 | 拟肽大环化合物 |
| SG11201503052RA (en) | 2012-11-01 | 2015-05-28 | Aileron Therapeutics Inc | Disubstituted amino acids and methods of preparation and use thereof |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| MX2017003797A (es) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| MX389354B (es) | 2014-09-24 | 2025-03-20 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y formulaciones de los mismos. |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| RU2762573C2 (ru) * | 2016-11-15 | 2021-12-21 | Новартис Аг | Доза и режим введения для ингибиторов взаимодействия hdm2 с p53 |
| EP3600326B1 (en) * | 2017-03-31 | 2023-01-25 | Novartis AG | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors |
| JP7358372B2 (ja) * | 2018-03-12 | 2023-10-10 | 羅欣薬業（上海）有限公司 | イミダゾピロロン化合物及びその使用 |
| US20210363254A1 (en) | 2018-03-20 | 2021-11-25 | Novartis Ag | Pharmaceutical combinations |
| IL319432A (en) * | 2018-04-30 | 2025-05-01 | Kartos Therapeutics Inc | Methods of treating cancer |
| AU2019273850B2 (en) | 2018-05-25 | 2024-11-14 | Kartos Therapeutics, Inc. | Methods of treating myeloproliferative neoplasms |
| CA3123356A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer |
| EP4031139A1 (en) | 2019-09-16 | 2022-07-27 | Novartis AG | Use of an mdm2 inhibitor for the treatment of myelofibrosis |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
| US20030139373A1 (en) | 2001-11-20 | 2003-07-24 | Breimer Lars Holger | Method for cancer therapy |
| EA019566B1 (ru) | 2005-02-22 | 2014-04-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Низкомолекулярные ингибиторы mdm2 |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| UA108746C2 (xx) * | 2009-12-22 | 2015-06-10 | Заміщені ізохінолінони та хіназолінони | |
| PL2361667T3 (pl) | 2010-02-25 | 2015-07-31 | General Electric Technology Gmbh | Płuczka wodna i sposób oczyszczania gazu procesowego |
| MX2013005238A (es) * | 2010-11-12 | 2013-09-02 | Univ Michigan | Antagonistas de mdm2 de espiro-oxindol. |
| CN103261229A (zh) * | 2010-12-16 | 2013-08-21 | 罗切格利卡特公司 | 无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法 |
| EP2741824B1 (en) | 2011-08-11 | 2017-05-03 | Estetra S.P.R.L. | Use of estetrol as emergency contraceptive |
| EP2793890B1 (en) | 2011-12-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
| US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| US20130245089A1 (en) | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
| PT2880447T (pt) | 2012-07-31 | 2019-08-02 | Novartis Ag | Marcadores associados à sensibilidade a inibidores de minuto duplo humano 2 (mdm2) |
| WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
| WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
| WO2015082384A1 (en) | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Novel combination treatment for acute myeloid leukemia (aml) |
| AU2014372167A1 (en) | 2013-12-23 | 2016-06-09 | Novartis Ag | Pharmaceutical combinations |
| DK3099717T3 (da) | 2014-01-31 | 2019-07-01 | Novartis Ag | Antistofmolekyler med tim-3 og anvendelser deraf |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| AU2016215035A1 (en) | 2015-02-06 | 2017-09-28 | Buck Institute For Research On Aging | Compounds and uses in treatment of senescence-associated conditions |
| HK1251165A1 (en) | 2015-04-13 | 2019-01-25 | Daiichi Sankyo Company, Limited | Treatment method combining mdm2 inhibitor and btk inhibitor |
| TWI804010B (zh) | 2015-08-03 | 2023-06-01 | 瑞士商諾華公司 | 作為血液學毒性生物標記之gdf-15 |
| ES2962460T3 (es) | 2015-08-28 | 2024-03-19 | Novartis Ag | Inhibidores de mdm2 y combinaciones de estos |
| RU2762573C2 (ru) | 2016-11-15 | 2021-12-21 | Новартис Аг | Доза и режим введения для ингибиторов взаимодействия hdm2 с p53 |
| US20190337952A1 (en) | 2016-11-22 | 2019-11-07 | Novartis Ag | Chemical Process for Preparing Imidazopyrrolidinone Derivatives and Intermediates Thereof |
| WO2018158225A1 (en) | 2017-02-28 | 2018-09-07 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof |
| EP3600326B1 (en) | 2017-03-31 | 2023-01-25 | Novartis AG | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors |
| US11406627B2 (en) | 2017-10-12 | 2022-08-09 | Novartis Ag | Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers |
| US20210363254A1 (en) | 2018-03-20 | 2021-11-25 | Novartis Ag | Pharmaceutical combinations |
| IL282485B2 (en) | 2018-10-30 | 2025-09-01 | Dana Farber Cancer Inst Inc | Compositions containing an mdm2 inhibitor and a cka1 inhibitor and/or an mdm4 inhibitor for use in the treatment of tumors with non-mutant p53 |
| CA3123356A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer |
| AU2020251019B2 (en) | 2019-04-04 | 2022-01-27 | Novartis Ag | Siremadlin succinate |
-
2015
- 2015-06-24 TW TW104120384A patent/TW201613576A/zh unknown
- 2015-06-25 EP EP15733926.8A patent/EP3160463B1/en active Active
- 2015-06-25 US US15/321,042 patent/US20170196866A1/en not_active Abandoned
- 2015-06-25 MX MX2016017075A patent/MX2016017075A/es unknown
- 2015-06-25 CN CN201580034558.4A patent/CN106456635A/zh not_active Withdrawn
- 2015-06-25 WO PCT/IB2015/054792 patent/WO2015198266A1/en not_active Ceased
- 2015-06-25 CN CN202211129314.2A patent/CN115569197A/zh not_active Withdrawn
- 2015-06-25 CA CA2953079A patent/CA2953079C/en active Active
- 2015-06-25 KR KR1020167035797A patent/KR102462177B1/ko active Active
- 2015-06-25 JP JP2016574274A patent/JP6728072B2/ja not_active Expired - Fee Related
- 2015-06-25 SG SG11201609853VA patent/SG11201609853VA/en unknown
- 2015-06-25 RU RU2017102319A patent/RU2695228C2/ru active
- 2015-06-25 AU AU2015278765A patent/AU2015278765B2/en not_active Ceased
- 2015-06-25 TN TN2016000522A patent/TN2016000522A1/en unknown
- 2015-06-25 KR KR1020247021711A patent/KR20240110659A/ko not_active Ceased
- 2015-06-25 KR KR1020227037821A patent/KR20220151027A/ko not_active Ceased
- 2015-06-25 BR BR112016029750A patent/BR112016029750A2/pt not_active Application Discontinuation
- 2015-06-25 ES ES15733926T patent/ES2856210T3/es active Active
-
2016
- 2016-11-22 IL IL249138A patent/IL249138B/en active IP Right Grant
- 2016-12-20 PH PH12016502556A patent/PH12016502556A1/en unknown
- 2016-12-22 CL CL2016003295A patent/CL2016003295A1/es unknown
-
2017
- 2017-12-21 US US15/849,770 patent/US20180110779A1/en not_active Abandoned
-
2018
- 2018-12-17 US US16/221,650 patent/US20190209561A1/en not_active Abandoned
-
2020
- 2020-06-11 US US16/898,886 patent/US11419870B2/en active Active
-
2022
- 2022-07-25 US US17/814,599 patent/US20230092181A1/en not_active Abandoned
-
2024
- 2024-04-11 US US18/632,528 patent/US20240261284A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016003295A1 (es) | Dosificación intermitente de un inhibidor de mdm2. | |
| CR20160237A (es) | Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CO2017012268A2 (es) | Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2020000122A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
| NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| UY35573A (es) | Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b | |
| NI201600115A (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| PE20151778A1 (es) | Formulacion combinada de dos compuestos antivirales | |
| CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| MX2019009853A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| UY34993A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| MX392839B (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
| UY35586A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CR20160203A (es) | Inhibidores de tirosina cinasa de bruton | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| CL2017001001A1 (es) | Derivados de carbazaol | |
| MX2018014220A (es) | Un dispositivo de vaporización, un procedimiento de uso del dispositivo, un estuche de carga, un kit y un conjunto de vibración. | |
| UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| MX381819B (es) | Derivados de heterociclico opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias. | |
| MX2016005142A (es) | Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos. | |
| CL2017000845A1 (es) | Inhibidores de gingipaina de lisina |